A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2006
11/16/2006	US20060258744 Medicament for preventing and/or treating peripheral neuropathies
11/16/2006	US20060258735 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
11/16/2006	US20060258729 Antibacterial pyrazole carboxylic acid hydrazides
11/16/2006	US20060258726 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
11/16/2006	US20060258716 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
11/16/2006	US20060258702 Stabilization of hypoxia inducible factor (HIF) alpha
11/16/2006	US20060258667 Method for improving respiratory function and inhibiting muscular degeneration
11/16/2006	US20060258660 Stabilization of hypoxia inducible factor (HIF) alpha
11/16/2006	US20060258658 Triazole compounds useful as protein kinase inhibitors
11/16/2006	US20060258569 Compounds and methods for treating cancer
11/16/2006	US20060257989 Truncated aggrecanase molecules
11/16/2006	US20060257987 Ppar modulators
11/16/2006	US20060257928 ANGE gene in atopy
11/16/2006	US20060257911 Of given nucleotide sequence; diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders
11/16/2006	US20060257850 Methods of treatment and diagnosis of patients with hepatitis c infection
11/16/2006	US20060257843 Kappa-PVIIA-related conotoxins as organ protectants
11/16/2006	US20060257474 anti-thrombocytic agent and an HMG-CoA reductase inhibitor in an amount sufficient to treat chronic glomerular nephritis wherein the anti-thrombocytic agent is selected from dilazep, dipyridamole and or salts thereof and the HMG-CoA reductase inhibitor is pitavastatin
11/16/2006	US20060257432 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucelic acid replication
11/16/2006	US20060257427 Molecule (antibody, peptide or chemical), coupled to a detectable label, cytotoxic agent or solid support, that specifically binds an extracellular portion of the latent viral membrane bound protein of Epstein-Barr Virus expressed in the latent viral membrane in the latent life cycle
11/16/2006	US20060257401 Sensitizing cells for apoptosis by selectively blocking cytokines
11/16/2006	US20060257367 Tumour-cell specific gene expression and its use in cancer therapy
11/16/2006	US20060257362 Method and composition for preventing and reating solid tumors
11/16/2006	US20060257329 Delivery of drug esters through an inhalation route
11/16/2006	DE102005021806A1 Verwendung von radikalfangenden Substanzen zur Behandlung von Zuständen mit erhöhter Hauttemperatur, insbesondere zur antipyretischen Behandlung Use of free radical scavenging substances for the treatment of conditions with increased skin temperature, especially for antipyretic treatment
11/16/2006	CA2618046A1 A method for modulating hla class ii tumor cell surface expression with a cytokine mixture
11/16/2006	CA2608643A1 Gene-based algorithmic cancer prognosis
11/16/2006	CA2608061A1 Pharmaceutical composition including an anti-tumoral and an active ingredient selected among carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	CA2608060A1 Composition for treatment or prevention of problems relating to a disturbance of the biological clock
11/16/2006	CA2608024A1 Use of flibanserin in the treatment of chronic pain
11/16/2006	CA2607561A1 Pharmaceutical composition
11/16/2006	CA2607044A1 Cardiovascular disease therapies
11/16/2006	CA2606887A1 Pharmaceutical composition
11/16/2006	CA2606875A1 Pharmaceutical combination including an antibiotic and an active ingredient selected among carveol, thymol, carvacrol, alpha-ionone and beta-ionone
11/16/2006	CA2606809A1 Trimeric ox40-immunoglobulin fusion protein and methods of use
11/16/2006	CA2606778A1 Vascular disease therapies
11/16/2006	CA2606535A1 Delivery of tigecycline in the presence of warfarin
11/16/2006	CA2604052A1 Methods and compositions for the treatment of cns-related conditions
11/16/2006	CA2603445A1 Anticancer combination therapy using sunitinib malate
11/15/2006	EP1721905A1 Thiazole derivative
11/15/2006	EP1721904A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
11/15/2006	EP1721608A2 Upregulation of type III endothelial cell nitric oxide synthase by HMG-CoA reductase inhibitors
11/15/2006	EP1721607A1 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
11/15/2006	EP1721606A2 Buffered compositions for dialysis
11/15/2006	EP1721604A1 Stable capsule preparation
11/15/2006	EP1720980A2 Treatment of spinal conditions
11/15/2006	EP1720610A1 Alcohol metabolism moderating composition
11/15/2006	EP1720577A2 Ciclesonide and glycopyrronium combination
11/15/2006	EP1720567A2 Composition and method for the treatment of carcinoma
11/15/2006	EP1720558A1 Composition and method for use in cartilage affecting conditions
11/15/2006	EP1720557A2 Rapidly disintegrating taste-masked tablet
11/15/2006	EP1720554A1 Use of meloxicam for the treatment of respiratory diseases in pigs
11/15/2006	EP1720540A2 Methods for treating resistant or refractory tumors
11/15/2006	EP1720536A1 Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
11/15/2006	EP1720511A1 Antimicrobial formulations and methods of using the same
11/15/2006	EP1720419A2 Nanoscale and supersaturated solutions of mineral or trace elements and a method for production of nanoparticles mixtures of nanoparticles, nanoscale solutions and general supersaturated solutions
11/15/2006	EP1720410A1 Compositions and methods for the treatment and clinical remission of psoriasis
11/15/2006	EP1599198B1 Potassium taurate bicarbonate and ascorbate complexes
11/15/2006	EP1547612A4 Medicinal agent and method for curing erectile dysfunction
11/15/2006	EP1511482B1 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
11/15/2006	EP1492519B1 Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators
11/15/2006	EP1474127B1 Biphenyl derivatives and their use as antiandrogenic agents
11/15/2006	EP1450799B1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
11/15/2006	EP1427718B1 Benzothiepine ileal bile acid transport inhibotors
11/15/2006	EP1410040B1 Method for identifying substances which modulate interleukin 4 (il-4) signaling
11/15/2006	EP1406899B1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
11/15/2006	EP1401434B1 Modulators of peroxisome proliferator activated receptors (ppar)
11/15/2006	EP1392692B1 (oxo-pyrazolo¬1,5a\|pyrimidin-2-yl)alkyl-carboxamides
11/15/2006	EP1389092B1 Abuse-resistant opioid dosage form
11/15/2006	EP1272197B1 Combination of lecithin with ascorbic acid
11/15/2006	EP1152731B1 A skin care composition that mediates cell to cell communication
11/15/2006	EP1093363B1 Compositions for treatment of disorders associated with chlamydia
11/15/2006	EP1019066B1 Methods and compositions for preventing and treating heartburn
11/15/2006	CN1863540A Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium
11/15/2006	CN1863539A Buffered compositions for dialysis
11/15/2006	CN1863531A Treatment for cd5+ b cell lymphoma
11/15/2006	CN1863511A Dosage forms of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors
11/15/2006	CN1863506A Methods for preparing oil bodies comprising active ingredients
11/15/2006	CN1861077A Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/15/2006	CN1861055A Composite slow-releasing anticarcinogen injection contg. platinum compounds
11/15/2006	CN1861054A Composite slow-releasing anticarcinogen contg. platinum compounds such as sunpla
11/15/2006	CN1861053A Slow-releasing injection contg. platinum compounds and cytotoxin type anticarcinogen
11/15/2006	CN1861052A Slow-releasing injection contg. platinum compound and cytotoxin type anticarcinogen
11/15/2006	CN1861051A Slow-releasing injection contg. platinum compounds and its potentiator type anticarcinogen
11/15/2006	CN1861050A Slow-releasing injection contg. platinum compounds and its potentiator type anticarcinogen
11/15/2006	CN1861049A Slow-releasing injection contg anticarcinogen of Jixitabin
11/15/2006	CN1861048A Slow-releasing injection contg. vasoinhibitor and cytotoxin type anticarcinogen
11/15/2006	CN1861047A Slow-releasing injection contg. vasoinhibitor and potentiator type anticarcinogen
11/15/2006	CN1861041A Temp-sensitive, slow-releasing gel used for local injection, and its prepn. method
11/15/2006	CN1284793C C-aryl glucoside sglt2 inhibitors
11/15/2006	CN1284536C Application of tetrodotoxin or saxitionxin and analogs thereof in preparation of general antalgic medicine application
11/15/2006	CN1284524C Application of solid liposome nanoparticle for preparing pharmaceutical used for ion leading-in trandermal therapy
11/15/2006	CN1284522C Dextrose and insulin fluid formulation for intravenous infusion
11/14/2006	US7135607 Shows symptoms of diffuse alveolar hemorrhage, glomerulonephritis, and appearance of antikidney glomerular basement membrane antibody; immunizing with type IV collagen homozygous transgenic mouse whose genome comprises a disruption of the FC gamma RIIB gene; diagnosis, drug screening
11/14/2006	US7135600 Selective beta 2-adrenoreceptor agonists; rapid onset of action, long duration; such as 3-(4-{[6-{(-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide; synthesis
11/14/2006	US7135501 Clusianon isomers and use thereof
11/14/2006	US7135481 Naphthalimide compositions and uses thereof
11/14/2006	US7135465 Sustained release beadlets containing stavudine
11/14/2006	US7135464 Method of administering decitabine
11/14/2006	US7135453 Reagents and methods for smooth muscle therapies
11/14/2006	US7135320 Adaptor protein FRS2 and related products and methods

1 ... 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 ... 1151